Immune escape and impaired immune surveillance have been identified as emerging hallmarks of cancer (1). Multiple Myeloma represents a genuine example of disrupted immune surveillance characterized by: impaired antibody production, deregulation of the T and NK cell compartment, disruption of antigen presentation machinery, upregulation of inhibitory surface ligands and recruitment of immunosuppressive cells. Although the potential value of immunotherapeutic interventions had a clear antecedent in the graft-versus-myeloma effect induced by allogeneic SCT and donor-lymphocyte infusions, it is only until recently that this field has faced a real revolution. In this review we discuss the current results obtained with immune approaches in patients with multiple myeloma that have placed this disease under the scope of immune-oncology bringing new therapeutic opportunities for the treatment of multiple myeloma patients.
- Received August 2, 2016.
- Accepted October 17, 2016.
- Copyright © 2017, Ferrata Storti Foundation